Sanara MedTech Inc.
SMTI · Price history
Price at last available close
$32.87
−$2.23 (-6.34%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Sanara MedTech Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties.
How they make money
Sanara MedTech Inc. generates revenue primarily by marketing and distributing surgical products, including soft tissue repair and bone fusion devices, to surgeons at hospitals and surgical centers in the United States. The company focuses on developing and commercializing transformative technologies designed to improve clinical outcomes and reduce healthcare expenditures in the surgical market.
Products & services
Surgical products including BiFORM Bioactive Moldable Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, and CellerateRX Surgical Activated Collagen.
Brands & revenue mix
Bioactive moldable matrix for bone fusion.
Separate brand revenue is not available in this research.Source
Advanced viable bone matrix containing progenitor cells.
Separate brand revenue is not available in this research.Source
Surgical activated collagen adjuvant.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company sells primarily to hospitals and surgical centers in the U.S.; no specific customer concentration figures were disclosed for the period ended 2025-12-31.
Suppliers, materials & equipment
- Contract Manufacturers — The company utilizes third-party contract manufacturers for the production of various surgical products; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Tufts University — A collaboration involving the formation of Sanara Collagen Peptides, LLC, where Tufts holds equity and provides licensed patents for the development and commercialization of new products.Source
Strengths
- Differentiated surgical technologies that address common surgical site complicationsSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
19
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
37
Poor
Financial Strength
25
Business Quality / Moat
76
Management
25
Growth Quality
30
Risk / Durability
7
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
31
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
43/100
Building Historical Record
Model Score 43/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •M&A headline · Aug 6, 2026
- •M&A headline · Aug 5, 2026
- •M&A headline · Aug 4, 2026
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for SMTI
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can SMTI maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is SMTI's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is SMTI's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for SMTI to reach sustainable profitability?
- •What future growth or profitability would be needed to justify SMTI's current valuation?
Essential Investment Snapshot
Wall Street Score
19
Opportunity Score
31
Market Cap
$300.8M
P/E Ratio
-8.9
EPS
$-3.72
52-Week High
$35.52
52-Week Low
$16.05
Beta
1.19
Analyst Target
$35.00
Shares Outstanding
8.6M
Total Revenue
$109.8M
Total Debt
$48.5M
Dividend
No current dividend
Liquidation Value / Share
$0.92
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for SMTI
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~1.4x). Earnings may be strained to cover interest expense.
M&A headline · Aug 6, 2026
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Aug 5, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--FBRX, LXFR, SMTI, and MKTX — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GuruFocusM&A headline · Aug 4, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on SMTI.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Differentiated surgical technologies that address common surgical site complications.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
- −Noncash asset impairment charges related to IP assets.
- −Strategic realignment and focus on surgical market products.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
19
Oct 1, 2026
Change
Unchanged
Current Score
19
Oct 19, 2026
Category Changes
SMTI score was unchanged.
Projected Score
Projected Score
20
Projected Change
+1.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 1.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$32.74
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.8M | $103.1M | $86.7M | $65.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $9.5M | $10.2M | $8.1M | $7.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $100.3M | $92.9M | $78.5M | $57.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $5.0M | $5.1M | $5.7M | $4.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $84.4M | $78.7M | $76.6M | $57.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $90.0M | $83.8M | $85.2M | $61.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $9.5M | $34.9M | -$1.9M | -$289K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $10.3M | $9.1M | -$6.7M | -$4.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $7.3M | $6.8M | $3.1M | $476K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$286K | -$393K | -$9.9M | -$4.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$32.0M | -$37.6M | -$9.7M | -$4.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.72 | $-4.36 | $-1.14 | $-0.52 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 8.66M | 8.62M | 8.48M | 8.28M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 8.66M | 8.62M | 8.48M | 8.28M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$28.1M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.05
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+6.8%
Cash Change
-9.1%
Margin Change
+6.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
What Weakened
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, net income margin. Pressure indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 8.9%. EPS declined 78.3%. Cash declined 9.1%. Total debt increased 6.8%. Net income margin improved by 6.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
15,945 Shares of Sanara MedTech Inc. $SMTI Bought by Bank of America Corp DE
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Rumor Mill · SMTI
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial